← All Sponsors
SPONSOR

GBG Forschungs GmbH

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 MutationBRCA2 Mutation
NCT06201234 Phase 2
Recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer
Germany View Trial →